GPX4 and diffuse large B-cell lymphoma: However, with the discovery that the prognosis of DLBCL patients with GPX4 positive and 8-hydroxydeoxyguanosine negative is significantly poorer in terms of OS (p = 0.0170) and PFS (p = 0.0005) (Kinowaki et al., 2018), researchers have begun to pay attention to the prognostic role of FRGs in DLBCL patients.